Lipitor Generics: Judge Questions Mylan's Right To Sue Over Marketing Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
During hearing, Judge Boasberg seemed skeptical that Mylan could seek a court order involving Ranbaxy's atorvastatin application when Mylan holds neither tentative approval nor first-filer status. A redacted ruling is expected to be released by May 4.
You may also be interested in...
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Judge Boasberg says the court should not "prematurely intrude" on FDA resolution of two factual issues: the approvability of Mylan's atorvastatin ANDA and any generic marketing exclusivity determination involving Ranbaxy.
Lipitor Generics: FDA Says Mylan Has No Standing To Sue (Until June 28?)
FDA is using a recent court decision involving ViroPharma’s antibiotic Vancocin to argue for dismissal of a Mylan Pharmaceuticals Inc. lawsuit that seeks a determination on generic marketing exclusivity rights for Pfizer’s Lipitor.